What Is Slowing Industrialization Of Korean Digital Healthcare?
Data Use Ambiguity, Regulatory Hurdles
Executive Summary
At a recent policy forum in Korea to discuss regulatory improvements, participants talked about the factors keeping the digital healthcare industry from taking off, despite ongoing efforts.
You may also be interested in...
New Korean Accounting Guidelines Aim For More Flexible Biopharma Practices
South Korea moves to lay out clearer accounting guidelines related to R&D costs for pharma and biotech companies, making improvements to earlier official guidance in 2018 in order to ease uncertainties and help foster the sector.
Hanmi Seeks To Swim In 'Blue Oceans' As It Expands Globally
At a recent forum in Seoul, an executive of Hanmi Pharmaceuticals, whose novel neutropenia drug has just received a US green light, shares why it is crucial to create "blue oceans" through global innovative drug development and how the Korean firm plans to challenge these markets.
Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.